Diarrhoeal disease is responsible for 8.6% of global child mortality. Recent epidemiological studies found the protozoan parasite Cryptosporidium to be a leading cause of paediatric diarrhoea, with particularly grave impact on infants and immunocompromised individuals. There is neither a vaccine nor an effective treatment. Here we establish a drug discovery process built on scalable phenotypic assays and mouse models that take advantage of transgenic parasites. Screening a library of compounds with anti-parasitic activity, we identify pyrazolopyridines as inhibitors of Cryptosporidium parvum and Cryptosporidium hominis. Oral treatment with the pyrazolopyridine KDU731 results in a potent reduction in intestinal infection of immunocompromised mice. Treatment also leads to rapid resolution of diarrhoea and dehydration in neonatal calves, a clinical model of cryptosporidiosis that closely resembles human infection. Our results suggest that the Cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase) is a target for pyrazolopyridines and that KDU731 warrants further preclinical evaluation as a drug candidate for the treatment of cryptosporidiosis.
Infections that cause diarrhoea are responsible for nearly 800,000 deaths every year, mostly among young children in resource-poor settings 1 . Recently, the apicomplexan parasite Cryptosporidium was found to be one of the leading causes of infectious diarrhoea in children 2, 3 , and infection with this parasite is strongly associated with mortality, growth stunting, and developmental deficits 4 . The major human pathogens causing cryptosporidiosis, C. hominis and C. parvum, infect the epithelial cells of the intestine and, through a mechanism that is not fully understood, trigger severe watery diarrhoeal symptoms. These are particularly long-lasting and often life-threatening in malnourished and immunocompromised children 4 . Nitazoxanide, the only approved drug for the treatment of cryptosporidiosis, has limited efficacy in these most vulnerable patient populations 5, 6 . Cryptosporidiosis is also a well-recognized opportunistic infection in adults with AIDS and transplant recipients 4 . Infection occurs through ingestion of the spore-like oocyst stage, which shows remarkable resistance to water chlorination. Therefore, even in countries that apply advanced water treatment, infection is common, and Cryptosporidium is the cause of 50% of disease outbreaks linked to recreational water use in the USA. The search for cryptosporidiosis therapeutics has been hindered by the many technical challenges faced when working with this notoriously intractable parasite 7 . Here we establish a drug-discovery screening process for cryptosporidiosis that combines phenotypic in vitro assays with novel animal models that take advantage of transgenic parasites 8 .
Cryptosporidium compound screen
To discover new treatments for cryptosporidiosis, we assembled a set of 6,220 compounds with known activity against various protozoan parasites and screened them against C. parvum in a high-content imaging infection assay in HCT-8 cells (see Supplementary Information) .
Notably, many anti-malarials (spiroindolones 9 , cyclomarins 10 , and imidazolopiperazines 11 ) lacked activity against Cryptosporidium; however, 154 compounds showed > 60% growth inhibition at 5 μ M. Secondary screening using a novel cytopathic effect (CPE)-based C. parvum assay confirmed several scaffolds, with imidazopyrazines 12, 13 and pyrazolo pyridines 14 showing sub-micromolar cellular activity ( Fig. 1a-d and Table 1 ; structures provided in Extended Data Fig. 1 ). We evaluated about 200 pyrazolopyridine analogues and found correlation between activity against C. parvum and Plasmodium falciparum (r 2 = 0.702; Fig. 1d ), suggesting that the mechanism of action of pyrazolopyridines is conserved between these two parasites. No such correlation was observed with toxicity against HepG2 (r 2 = 0.071) (Extended Data Fig. 2 ). C. hominis is responsible for most clinical infections 15 . We thus evaluated a subset of pyrazolopyridine analogues against C. hominis, and found potency comparable to that against C. parvum (r 2 = 0.872; Fig. 1e and Table 1 ).
Pyrazolopyridines inhibit CpPI(4)K
Knowing that pyrazolopyridines and imidazopyrazines exert their antimalarial activity through inhibition of the Plasmodium lipid kinase PI(4)K 12,16 , we searched for potential Cryptosporidium orthologues. The genomes of both C. parvum and C. hominis encode multiple putative lipid kinases, and the PI(4)K catalytic domain of cgd8_4500 and its C. hominis homologue Chro.80518 show 71.8% amino-acid sequence similarity to P. falciparum PI(4)K. We expressed cgd8_4500 in insect cells and purified the protein (CpPI(4)K), which displays phosphatidylinositol kinase activity with a Michaelis constant (K m ) for ATP and phosphatidylinositol of 3 and 0.4 μ M, respectively (Extended Data Fig. 3 ). Using this assay, we showed that the imidazopyrazine KDU691 and the pyrazolopyridine KDU731 are potent inhibitors of CpPI(4)K enzymatic activity with half-maximal inhibitory concentration (IC 50 ) values of 17 and 25 nM, respectively ( Fig. 1f ). Both compounds have a > 50-fold selectivity window against the human PI(4)K IIIβ homologue (Extended Data Table 1 ).
When we measured diverse imidazopyrazine and pyrazolopyridine analogues against CpPI(4)K enzymatic activity and C. parvum growth in cells, we found a tight correlation (r 2 = 0.902) ( Fig. 1g ), suggesting that the anti-Cryptosporidium activity is directly mediated by CpPI(4)K inhibition. Further genetic and structural insights are needed to unambiguously establish PI4(K) as the target. However, we note that the Plasmodium PI(4)K inhibitors diaryl-aminopyridine (MMV390048) 17 and quinoxaline (BQR695) 12 , which are inactive against C. parvum and C. hominis, do not inhibit CpPI(4)K enzymatic activity ( Fig. 1f ). Finally, mechanistic studies revealed an increased K m for ATP in the presence of KDU731 ( Fig. 1h ), suggesting ATP-competitive inhibition similar to that previously observed for the Plasmodium enzyme 12 . Additional structure-activity relationship analysis of pyrazolopyridines against Cryptosporidium is found in the Supplementary Information. Taken together, our data suggest that pyrazolopyridines are inhibitors of CpPI(4)K that bind to the ATP-binding site of the enzyme with a favourable selectivity window over human PI(4)K.
Pharmacokinetic properties of KDU731
The most urgent need for effective cryptosporidiosis treatment is among children under the age of 2 years. A very safe drug profile is thus a key component of the target product profile 18, 19 . KDU731 has a selectivity index of more than 100 (half-maximal cytotoxicity concentration (CC 50 ) of HepG2 = 15.6 μ M and half-maximal effective concentration (EC 50 ) of C. parvum CPE = 0.1 μ M) (Extended Data Table 1 ). In a battery of safety pharmacology assays, the compound does not show intrinsic risks for cardiotoxicity, mutagenicity, clastogenicity, or phototoxicity, and it does not bind significantly to a panel of human anti-targets (Extended Data Tables 1 and 2). KDU731 safety was further evaluated in a 2-week toxicology study in rats using a solid dispersion formulation to maximize systemic exposure (~ 25-fold). In this study, no significant histopathological changes and only minor changes in clinical chemistry and haematology were observed (slight elevation of cholesterol and phosphate 
Table 1 | Activity of pyrazolopyridine analogues and other known PI(4) kinase inhibitors
Compound Article reSeArcH ions and increase in red blood cells, see Supplementary Information). Importantly, no haematopoietic toxicity related to potential inhibition of PI3K or PI4K lipid kinases was observed, suggesting that the in vitro selectivity of KDU731 translated to lack of host toxicity in vivo (Extended Data Table 1 ). Children with cryptosporidiosis in resource-limited settings frequently suffer comorbidities including HIV, tuberculosis, and other infections; anti-cryptosporidial drugs will thus probably be used along with other medications, and the risk of drug-drug interactions needs to be minimized. Consistent with the requirement, KDU731 did not inhibit any of the major cytochrome P450 isoenzymes and did not induce human pregnane X receptor (Extended Data Table 1 ). KDU731 pharmacokinetics, metabolism, and distribution were examined in mice, rats, and rhesus monkeys. Upon intravenous administration, KDU731 displayed a low-to-moderate volume of distribution (V ss = 1.12 and 2.15 l kg −1 ), a low total systemic clearance (CL = 6.8 and 16 ml min −1 kg −1 ), and a half-life ranging from 1 to 4 h (Extended Data Table 3 ). KDU731 orally administered in suspension formulation displayed a moderate half-life (t 1/2 = 2-4 h) in all three species. KDU731 was selected as a drug candidate because it shows moderate-to-low oral bioavailability (37% in rodents, 9% in nonhuman primates). As Cryptosporidium primarily infects the intestinal epithelium, we reasoned that systemic exposure may not be required for efficacy and that limiting systemic exposure may further enhance the safety margin of a cryptosporidiosis drug.
KDU731 treatment of infected mice
Current assessment of cryptosporidiosis treatments relies on laborious methods to quantify the parasite in animals. We used genetically modified parasites to build more facile models. We established the EC 50 of KDU731 for transgenic parasites 8 in HCT-8 using Nanoluciferase (Nluc) as a readout and found it comparable to the EC 50 for wild-type parasites (Extended Data Fig. 4a ). Next, we inoculated 6-to 8-weekold C57BL/6 interferon-γ (IFN-γ )-knockout mice with 10,000 oocysts and monitored infection by following parasite-derived luciferase activity in the faeces (Fig. 2a ). Infected mice were treated orally with KDU731 in suspension formulation and parasite load was measured in the pooled faeces by Nluc and quantitative PCR (qPCR) assay with a high degree of correlation (Spearman coefficient = 0.786; two-tailed P = 0.048). The Nluc assay has a small sample requirement (20 mg) and thus could be conducted on individual mice as well as pooled faeces (unpaired t-test comparing means of individual and pooled readings showed no significant difference, two-tailed P = 0.3862). Importantly, KDU731 greatly reduced oocyst shedding regardless of assay method ( Fig. 2b and Extended Data Fig. 4b, c ; non-parametric Kruskal-Wallis test, pooled Nluc two-tailed P < 0.001; faecal qPCR two-tailed P = 0.0042). In a modified design, KDU731 (10 mg per kg (body weight)) treatment was initiated at the peak of infection, again resulting in a significant reduction in oocyst shedding (Fig. 2a, c) . At the end of the treatment period, three mice per group were killed and intestines were processed for histology. We did not observe parasites in the intestines of treated animals, whereas those that received vehicle showed substantial infection (Fig. 2d) .
To dynamically evaluate the impact of treatment on parasite load directly in the intestinal tissue, we engineered a new reporter parasite amenable to detection by whole-animal imaging. Mice were infected with parasites expressing red-shifted firefly luciferase 20 (Fluc) and imaged after d-luciferin injection. Intestinal tissue load was quantified by PCR and we found strong correlation with tissue luminescence (r 2 = 0.8; Extended Data Fig. 5a, b ). KDU731 treatment of mice infected with Fluc parasites was initiated on day 7, when all mice registered high levels of abdominal luciferase activity and mice were imaged daily. Tissue load dropped markedly within 2 days of treatment, and fell below the limit of detection after 5 days ( Fig. 2e, g) . Changes in luminescence imaging were mirrored by faecal oocyst shedding quantified by PCR (Spearman coefficient = 0.840, two-tailed P = 0.0006; Extended Data Fig. 5c ). For comparison, we evaluated nitazoxanide at 100 mg per kg (body weight) and observed no change ( Fig. 2f and Extended Data Fig. 6 ), consistent with previous reports on immunosuppressed hosts 5, 21 .
Treatment of neonatal calves
Newborn calves are naturally susceptible to C. parvum infection, resulting in faecal oocyst shedding, profuse watery diarrhoea, and severe dehydration, which closely mirrors human symptomology 22,23 . We challenged 13 neonatal calves with 5 × 10 7 oocysts. Over the duration of enrolment, a complete physical examination was performed every 12 h and clinical data including appetite, mentation, faecal consistency, and hydration status were recorded (Fig. 3) to assign a clinical score on a scale of 1 (normal) to 3 (severe) in accordance with previously described methods (see rubric in Supplementary Information) 22-24 . Faecal oocyst shedding was enumerated every 24 h by qPCR. The treatment group (n = 7) was subjected to oral treatment with 5 mg per kg (body weight) KDU731 in suspension formulation every 12 h for 7 days. Treatment was initiated upon development of fulminant diarrhoea and faecal oocyst shedding, between day 2 and day 4 after infection.
All calves tolerated KDU731 treatment without compound-related abnormalities, and treated calves shed significantly fewer oocysts than vehicle-treated calves within 3 days of treatment (P < 0.0001 on day 3) ( Fig. 3b ). Treated calves suffered fewer days of severe diarrhoea (two-tailed P = 0.006) and were significantly less dehydrated (two-tailed P < 0.0001) than controls ( Fig. 3c, d ). Resolution of clinical signs started as early as 24 h after treatment was initiated. Within 48 h of treatment, six out of seven calves showed no signs of dehydration, and within 72 h of treatment five of six calves had resolution of severe diarrhoea (Extended Data Fig. 7 ). KDU731 displayed limited systemic exposure in calves with a maximum serum concentration (C max ) and an absorption (area under the concentration-time curve, AUC) of 0.228 μ M and 1.9 μ M h −1 respectively ( Fig. 3e and Extended Data Table 3 ), confirming that substantial systemic exposure may not be required for parasite clearance and resolution of clinical illness.
Conclusions
Our studies define the pyrazolopyridine KDU731 as a promising anti-cryptosporidial drug candidate that is active against both C. parvum and C. hominis. Unlike nitazoxanide, KDU731 demonstrated in vivo efficacy in immunocompromised mice. Additionally, treatment in neonatal calves, which closely matches the pathophysiological and pharmacological challenges faced in the treatment of young malnourished children, led to a significant decrease in parasite shedding and rapid resolution of diarrhoea and dehydration. Our lead candidate, KDU731, displays good anti-cryptosporidial activity and meets a broad range of safety and pharmacology criteria required for a much-needed novel cryptosporidiosis therapeutic intervention. Further safety and pharmacological preclinical evaluation is currently ongoing to support the initiation of human clinical trials. , d) as a 'box and whiskers' plot; the box extends from the 25th to 75th percentiles, and whiskers with minimum to maximum showing all data points. Data in b and e were determined to display non-Gaussian distribution and were log-transformed before statistical analysis using t-tests with two-tailed * P < 0.05, * * 0.01, * * * 0.001, and * * * * 0.0001; data in c and d were determined to be normally distributed and analysed using t-tests.
Article reSeArcH 3 days of quarantine and acclimatization before study begin. All animals were subjected to daily clinical observation, and body weight and food consumption were determined for all animals enrolled in the study. Clinical laboratory evaluations (haematology and clinical chemistry) were performed at the scheduled necropsy on day 15. Organs were examined for gross pathology and weighed before fixation and preparation for histology. Samples from organs and tissues prepared from animals assigned to control and high-dose groups were examined microscopically. Specifically, the heart, pancreas, gastrointestinal tract (oesophagus, stomach, duodenum, jejunum, ileum, caecum, colon, rectum), kidney, liver, spleen, lung, testes, epididymis, adrenals, and thymus were examined for histopathological changes.
Engineering of a C. parvum transgenic parasite strain expressing red-shifted Fluc. The 5′ untranslated region (UTR) and 3′ UTR of the C. parvum actin gene were amplified from parasite genomic DNA and ligated into the KpnI/ClaI and SpeI/BamHI sites of plasmid TK-Eno-Nluc-Neo-TK 8 , respectively. The coding sequence for red-shifted luciferase 20 was amplified from pTubRE9 vector (a gift from M. Meissner, University of Glasgow, UK) and cloned into SalI/NheI restriction sites replacing Nluc. A 404-base-pair fragment of the 5′ TK flank, the tk gene, and a ribosomal 3′ UTR were inserted upstream of the 5′ actin UTR using Gibson Assembly cloning (New England Biolabs). The final vector, along with the Cas9 plasmid containing a TK guide RNA (GAAGAATACAATTTCTAAGG) targeting the 3′ end of the tk gene, was used to transfect C. parvum sporozoites. Sporozoites were delivered by surgery into the small intestine of C57BL/6 IFN-γ knockout mice (B6.129S7-Ifngtm1Ts/J, Jackson Laboratory) using procedures described previously 8 . Note that UGA1 Nluc parasites were generated using C. parvum IOWA II oocysts purchased from Sterling Parasitology Laboratory, University of Arizona, whereas the UGA2 Fluc strain was engineered using C. parvum IOWA II oocysts purchased from Bunch Grass Farms, Deary, Idaho, USA. Mouse model following faecal oocyst load. All mouse studies described in this section were approved by the Institutional Animal Care and Use Committee of the University of Georgia (animal use protocol number A2016 01-028-Y1-A4). C57BL/6 IFN-γ knockout mice aged 6-8 weeks were selected randomly for each group (n = 5) and infected with 10,000 C. parvum UGA1 Nluc 8 oocysts. No statistical tests were used to predetermine sample size. KDU731 was formulated in 0.5% (w/v) methylcellulose and 0.5% (w/v) polysorbate in water and administered to mice daily for 7 days by oral gavage beginning on day 3 or day 11 after infection. Control mice were given only vehicle. Mice were monitored for weight loss, fur ruffling, hunched posture, and inactivity. Mice showing a weight loss of equal to or greater than 15% were euthanized. Faecal samples were collected (not blinded) and luminescence measurements were performed as described 8 (parasite Nluc activity is stable in faeces when refrigerated). Measurements were performed on faeces collected from individual mice as well as from cage-wide (pooled) collections. For Nluc assay, 20 mg of faeces was mashed in 1 ml of lysis buffer (50 mM Tris-HCl (pH 7.6), 2 mM DTT, 2 mM EDTA, 10% glycerol, 1% Triton X-100), ten 3-mm glass beads were added to the tube, followed by vigorous agitation using a vortex mixer for 1 min and a short spin to pellet faecal material. Three aliquots of 100 μ l lysate were dispensed into 96-well white plates and an equal amount of Nano-Glo reconstituted buffer containing 1:50 of Nano-Glo substrate (Promega) was added, luminescence was read using a Synergy H4 Hybrid Microplate Reader (BioTek Instruments).
To measure oocyst load by qPCR, DNA was isolated from 100 mg of faeces. Samples were subjected to five rounds of freezing in liquid nitrogen and thawing in 100 °C heater block before DNA isolation using a ZR Faecal DNA Miniprep Kit (Zymo Research, Irvine, California, USA). qPCR was performed using sample DNA along with standards prepared from uninfected faeces spiked with oocysts. PCR primers JVAF and JAVR and probe 5′ FAM-labelled JVAR 33 were used along with the following cycling parameters: denaturation at 95 °C for 3 min, followed by 40 cycles of denaturation at 95 °C for 10 s, and annealing at 60 °C for 30 s. Each 20 μ l PCR reaction contained 10 μ l of SSoAdvanced Universal Probes Supermix (Bio-Rad Laboratories, Hercules, California, USA), 0.4375 μ M of each primer, 0.125 μ M probe, and 2 μ l DNA. Mouse model following tissue parasite load using whole-animal imaging. IFN-γ knockout mice (n = 5 per group) were infected with 10,000 C. parvum UGA2 Fluc oocysts expressing red-shifted Fluc and given a daily dose of 10 mg per kg (body weight) KDU731, nitazoxanide (Sigma) at 100 mg per kg (body weight), or control formulation for one week by oral gavage starting on day 7 after infection. Parasite tissue load was measured by in vivo imaging. At the beginning of the experiment, the abdominal area of mice was shaved with clippers to increase the signal during imaging on an IVIS Lumina II system (Caliper Life Sciences). Mice were injected subcutaneously with 125 mg per kg (body weight) d-luciferin (Gold Biotechnology, St Louis, Missouri, USA). Five minutes after luciferin injection, mice were anaesthetized in an induction chamber using 3% isofluorane and then placed in the camera chamber. Mice were kept under anaesthesia by administering isofluorane through individual nose cones. Images were acquired using a setting of F-stop = 1/16, binning = medium, and an exposure time of 5 min. Regions of interest were selected for each mouse and total flux (photons per second) was quantified using IVIS Lumina II Living Image 4.0 Software (Caliper Life Sciences). To validate measurements of parasite tissue burden, mice infected for 1 week were imaged, killed, and the small intestine was removed and cut into 12 (1-cm) segments, and flushed with PBS. Sections were imaged three times in PBS with d-luciferin, after which genomic DNA was isolated from each segment using a ZR Faecal DNA Miniprep Kit (Zymo Research, Irvine, California, USA). qPCR was performed using the parameters described above and parasite burden was established against a standard curve of samples with known parasite DNA content. Histology of intestinal tissue. Mice treated with KDU731 or control formulation were killed and intestinal tissue was collected within 15 min of death. Sections of the small intestine were taken from the 1-2 cm region anterior to the caecum, flushed with PBS, and fixed overnight in 10% buffered formalin. Fixed samples were embedded in paraffin and 4 μ m sections were cut (RM225 Microtome, Leica, Buffalo Grove, Illinois, USA). Sections were de-paraffinized and stained with haematoxylin and eosin. Neonatal calf efficacy study. All calves used in this study were cared for in compliance with the Washington State University Institutional Animal Care and Use Committee. Sample size was calculated assuming that 85% of treated calves had resolution of clinical illness by the end of the treatment period (48 h after administration of treatment number 14) compared with 15% of control calves. Assuming a type I error risk of 5% and a type II error risk of 80%, seven calves were needed in the treatment group, plus two positive controls. In the event of calf death or removal from the study, an additional four calves were added to the control group (n = 6). Sample size was calculated using Epi Info. Fifteen Friesian-Holstein bull calves were enrolled in November 2015 and February 2016. At birth, all calves enrolled in November were randomized to treatment with KDU731 (n = 7), positive infection control (n = 2), and negative infection control (n = 1). The five calves enrolled in February were positive controls. The perineum of the dam was cleaned with povidone-iodine scrub, and calves were delivered onto single-use plastic sheets to prevent exposure to environmental pathogens. Calves with abnormal physical examination findings and those weighing less than 29.5 kg at birth were excluded. Enrolled calves received 4 l ≥ 50 g IgG/l commercial colostrum replacer (Land O'Lakes) and a 3 ml subcutaneous injection of vitamin E and selenium (Merck Animal Health). Calves were then transported from the commercial dairy farm to Washington State University where they were housed in individual box stalls in a BSL-2 facility. Shatter-proof mirrors were provided for enrichment. Within 48 h of birth, blood samples were collected and evaluated for adequate passive transfer of colostral immunity. Calves were offered a commercial 20% protein/20% fat non-medicated milk replacer (Land O'Lakes) every 12 h via nipple bucket. At each feeding, calves were fed an average of 8.8 g of dry matter per kilogram of birth weight for the duration of the study. Water was provided ad libitum. All calves randomized to treatment or positive control groups were experimentally challenged within the first 48 h of life with 5 × 10 7 C. parvum oocysts (Iowa II, Bunch Grass Farm, ID) through the rigid portion of an oroesophageal feeding tube. Oocysts were within 1 month of isolation and were cleaned in 0.6% sodium hypochlorite for 1 min and then washed four times with PBS. The negative control calf was sham-challenged to maintain blinding of study personnel.
To facilitate collection of blood for plasma pharmacokinetic analysis, a longterm intravenous catheter (MILACATH, MILA International) was aseptically placed in the jugular vein within the first 48-72 h of life. Calves were sedated with 0.1 ml intravenous xylazine (20 mg ml −1 ) (Akorn Animal Health). Sedation was reversed with 0.1 ml intramuscular atipamezole (5 mg ml −1 ) (Zoetis). Beginning at birth, a faecal sample was collected directly from the rectum every 24 h. A complete physical examination was performed every 12 h, and clinical data including appetite, mentation, faecal consistency, and hydration status were recorded. Clinical data were evaluated on a scale of 1 (normal) to 3 (severe) in accordance with previously described methods (see rubric in Supplementary Information) 23,24 .
KDU731 was prepared as a 5 mg ml −1 suspension formulation in 0.5% (w/v) methylcellulose and 0.5% w/v Tween-80 in water, and KDU731 treatment was initiated when a calf began shedding oocysts and had a faecal consistency score of 3. Calves were induced to suckle and then KDU731 was given orally via an oral dosing syringe. Calves were treated every 12 h for 7 days at a dose of 5 mg per kg birthweight at least 2 h after feeding. Pharmacokinetic sampling was conducted on day 1 and day 7 of treatment. Blood was drawn before and at multiple time-points after administration. A faecal sample was collected 1 h and 12 h after administration. On days 2-6 of treatment, blood was collected before KDU731 administration. On day 3 of life, a faecal sample was tested for E. coli K99, and on day 7 for Salmonella, rotavirus, and corona virus. Of the seven treatment calves, two (N101 and N107) were randomly selected to be euthanized 24 h after administration of the final KDU731 treatment. A positive control calf (N104) was also euthanized at the same
